Autonomous Therapeutics wins $1 million Blue Knight™ QuickFire Challenge

Written By Ariel Weinberger

Autonomous Therapeutics has received a $1 million award from the BLUE KNIGHT™ Resident QuickFire Challenge to use its encrypted RNA platform technology to develop a next-generation prophylactic that provides single-dose, months-long protection against every variant of SARS-CoV-2.

BLUE KNIGHT is a joint initiative between the Biomedical Advanced Research and Development Authority (BARDA) and Johnson & Johnson Innovation – JLABS.

Ariel Weinberger
Previous

Autonomous CEO, Dr. Ariel Weinberger, gives plenary presentation at NIH Synthetic Biology Consortium Meeting
Next

Keynote Panel @ RNA Leaders USA Congress